European Commission Approves Gilead’s BiktarvyApprovals, European Commission, FDA/Regulatory, HIV, Nucleoside Reverse Transcriptase InhibitorsThe European Commission granted Marketing Authorization for Gilead Sciences Inc.’s Biktarvy as a once-daily single tablet regimen for the treatment of HIV-1 infection. Read more June 25, 2018/by Business Wire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Business Wire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Business Wire2018-06-25 08:03:012018-06-25 09:45:43European Commission Approves Gilead’s Biktarvy
